Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Oral Semaglutide Wins FDA Approval to Reduce Risk of MACE in Adults with T2D at High Risk
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

October 20th 2025

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose / Image credit: ©New Africa/AdobeStock
Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose

October 16th 2025

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D  / image credit ©Gecko Studio/stock.adobe.com
Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D

October 15th 2025

Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials  / image credit ©MichaelVi/stock.adobe.com
Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials

October 15th 2025

FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents
FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents with Diabetes

October 13th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.